Log In
BCIQ
Print this Print this
 

Orencia, abatacept (subcutaneous) (BMS-188667SC, ONO-4164 SC)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionSubcutaneous formulation of abatacept, a CTLA-4 (CD152)-Ig fusion protein
Molecular Target CD80 (B7-1) ; CD86 (B7-2)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today